To this end, we employed two syngeneic triple negative murine breast tumor models (4T1 and E0771) and used the transforming growth factor (TGF)-β inhibitor tranilast (Rizaben), a clinically approved antihistamine and anti-fibrotic drug, as the normalization agent alone or in combination with doxorubicin or its nanoparticle formulation Doxil (~100 nm, PEGylated liposomal doxorubicin). This evidence concerns the gene TGFB1 and breast neoplasm.